DexCom, Inc. $DXCM Stock Sold by SBI Okasan Asset Management Co.Ltd.

SBI Okasan Asset Management Co.Ltd. lowered its stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 35.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,705 shares of the medical device company’s stock after selling 9,800 shares during the quarter. SBI Okasan Asset Management Co.Ltd.’s holdings in DexCom were worth $1,534,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in DXCM. Teachers Retirement System of The State of Kentucky lifted its holdings in shares of DexCom by 27.8% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 358,931 shares of the medical device company’s stock worth $30,973,000 after buying an additional 78,026 shares in the last quarter. HighTower Advisors LLC boosted its position in shares of DexCom by 13.2% in the third quarter. HighTower Advisors LLC now owns 120,646 shares of the medical device company’s stock valued at $10,411,000 after acquiring an additional 14,066 shares during the period. BCS Private Wealth Management Inc. boosted its position in shares of DexCom by 4.4% in the third quarter. BCS Private Wealth Management Inc. now owns 6,895 shares of the medical device company’s stock valued at $595,000 after acquiring an additional 290 shares during the period. Intech Investment Management LLC boosted its position in shares of DexCom by 376.2% in the third quarter. Intech Investment Management LLC now owns 117,774 shares of the medical device company’s stock valued at $10,163,000 after acquiring an additional 93,040 shares during the period. Finally, Geneva Capital Management LLC grew its stake in DexCom by 14.3% during the third quarter. Geneva Capital Management LLC now owns 149,856 shares of the medical device company’s stock valued at $12,931,000 after acquiring an additional 18,773 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, EVP Jereme Sylvain sold 3,638 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president owned 146,828 shares in the company, valued at approximately $12,226,367.56. This trade represents a 2.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of the firm’s stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $78.62, for a total transaction of $201,660.30. Following the sale, the executive vice president owned 120,913 shares in the company, valued at approximately $9,506,180.06. This trade represents a 2.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 22,822 shares of company stock valued at $1,920,193. Company insiders own 0.28% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of analyst reports. UBS Group upped their target price on shares of DexCom from $102.00 to $107.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Canaccord Genuity Group increased their target price on shares of DexCom from $90.00 to $97.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Argus raised their price target on shares of DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Mizuho set a $100.00 price target on shares of DexCom in a research report on Tuesday, October 13th. Finally, Robert W. Baird set a $105.00 price target on shares of DexCom and gave the company an “outperform” rating in a research report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, DexCom has a consensus rating of “Buy” and a consensus target price of $95.50.

Read Our Latest Report on DXCM

DexCom Stock Performance

NASDAQ:DXCM opened at $81.61 on Tuesday. The stock has a market cap of $30.44 billion, a P/E ratio of 32.00, a PEG ratio of 1.34 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.74 and a debt-to-equity ratio of 0.49. The business’s 50-day moving average price is $84.17 and its two-hundred day moving average price is $75.25. DexCom, Inc. has a twelve month low of $56.72 and a twelve month high of $92.59.

DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.68 by $0.05. The company had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. DexCom’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.61 earnings per share. As a group, equities analysts predict that DexCom, Inc. will post 2.68 EPS for the current fiscal year.

DexCom Profile

(Free Report)

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

Read More

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.